Analysts Set Expectations for Immunic FY2026 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings of ($0.98) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

Several other research analysts also recently commented on IMUX. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. Finally, D. Boral Capital restated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Immunic currently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

NASDAQ IMUX opened at $1.24 on Thursday. The stock has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.21. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11. The stock has a market capitalization of $111.70 million, a PE ratio of -1.01 and a beta of 1.89.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after buying an additional 96,894 shares in the last quarter. Millennium Management LLC increased its stake in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares during the period. Focus Partners Wealth raised its position in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Bridgeway Capital Management LLC lifted its stake in Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares during the period. Finally, 683 Capital Management LLC raised its stake in Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after acquiring an additional 15,349 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.